Vaccibody raises NOK220M in private placement

Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares at NOK250 in a private placement with new and existing investors.

Vaccibody develops personalized cancer neoantigen vaccines. Its VB10.16 is in Phase I/II testing to treat HPV type 16-associated cervical intraepithelial neoplasia (CIN) grade 2/3. The DNA-based immunotherapy, which is delivered by the PharmaJet Stratis needle-free injection system, targets HPV type 16-induced pre-malignancies and malignancies...